

Financial Tear Sheet

Corporate Profile


We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. We have built a core platform, which we call Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Our integrated platform has a full complement of in-house capabilities for human genetics and small molecule drug discovery, and for pre-clinical and clinical development.

Stock Performance

XENE (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$2.95
Change (%)	0.00 (0.00%)
Volume	29,567
52 Week Low	\$2.10
Market Cap	\$53,095,339
Rolling EPS	-1.59
PE Ratio	0
Shares Outstanding	17,998,420

Data as of 01/23/18 3:59 p.m. ET



Recent Press Releases & Upcoming Events

January 8, 2018 - Xenon Pharmaceuticals Outlines Key Milestones for 2018

There are currently no events scheduled.

December 4, 2017 - Positive Preclinical Data from Xenon's XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting

November 8, 2017 - Xenon Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference

SEC Filings

Filing Date	Form
01/08/18	8-K
12/18/17	8-K
11/16/17	4
11/07/17	10-Q

Corporate Governance

Simon Pimstone, MBChB, Ph.D., FRCPC

Ian Mortimer, MBA, CPA, CMA

Y. Paul Goldberg, MBChB, Ph.D., FRCPC

Robin Sherrington, Ph.D.

Charles Cohen, PhD

James Empfield, Ph.D.

Data provided by Nasdaq. Minimum 15 minutes delayed. View [Attributions and Sources](#)